title: [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
abstract: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity that accounts for less than 5% of the cases of Hodgkin lymphoma (HL) with morphological, immunophenotypical, genetic and clinical behavior traits different from the classic HL. In a minority of patients, the NLPHL course is complicated by a transformation to a non-Hodgkin diffuse large B-cell lymphoma (NHDLBCL) with prognostic and therapeutic implications. Early metabolic changes observed by (18)F-FDG PET in patients with HL and NHL, after 1-3 cycles of chemotherapy, predict the final response to treatment and progression-free survival. In the case we are presenting herein, whether NLPHL is transformed to NHDLBCL or the two types of lymphoma co-exist in the same patient, the (18)F-FDG PET/CT scan was crucial for the identification of tumor resistance to first line chemotherapy and to guide a second biopsy decision and therefore modify the chemotherapy regimen.
authors.affiliation: Unidad de Medicina Nuclear, Grupo Hospitalario Quirón La Floresta, Zaragoza, España. jbanzoma@unizar.es
authors.forename: J
authors.initials: J
authors.lastname: Banzo
authors.forename: M A
authors.initials: MA
authors.lastname: Ubieto
authors.forename: P
authors.initials: P
authors.lastname: Giraldo
authors.forename: P
authors.initials: P
authors.lastname: Razola
authors.forename: E
authors.initials: E
authors.lastname: Prats
authors.forename: L
authors.initials: L
authors.lastname: Tardin
authors.forename: A
authors.initials: A
authors.lastname: Santapau
authors.forename: A
authors.initials: A
authors.lastname: Parra
authors.forename: E F
authors.initials: EF
authors.lastname: Rambalde
authors.forename: J
authors.initials: J
authors.lastname: Velilla
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001706:Biopsy; D001761:Bleomycin / Q000008:administration & dosage / Q000494:pharmacology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage / Q000494:pharmacology; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D019275:Radiopharmaceuticals; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D014057:Tomography, X-Ray Computed; D018084:Ultrasonography, Interventional; D014747:Vinblastine / Q000008:administration & dosage / Q000494:pharmacology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D001761:Bleomycin; D000069283:Rituximab; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone